Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis.
Tzu-Rong PengYi-Fang WengTa-Wei WuChao-Chuan WuYi-Chun ChouChing-Sheng HsuPublished in: Cancers (2024)
Sorafenib or lenvatinib can provide effective treatment with manageable toxicity in patients with advanced HCC after disease progression under atezolizumab-bevacizumab.